NWBO (Northwest Biotherapeutics) GF Value Rank : 0 (As of Apr. 15, 2025)

View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics GF Value Rank?

Northwest Biotherapeutics has the GF Value Rank of 0.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Northwest Biotherapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Executives

Navid Malik	director	1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch	officer: Chief Technical Officer	22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton	director, officer: Chief Scientific Officer	22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman	officer: See Remarks	C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers	director, 10 percent owner, officer: President and CEO	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski	director	C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis	officer: See Remarks	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh	director	WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer	director	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp	10 percent owner	27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund	10 percent owner	C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc.	10 percent owner	7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer	director	10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr.	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814